Skip to content

Effect of Noni Juice on Lipid Peroxidation-derived DNA Adducts in Heavy Smokers

Double Blind, Randomized, Placebo-controlled Clinical Trial of the Effect of Noni Juice on Lipid Peroxidation-derived DNA Adducts in Current Heavy Smokers

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01677169
Enrollment
317
Registered
2012-08-31
Start date
2000-09-30
Completion date
2006-08-31
Last updated
2019-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DNA Damage

Brief summary

The purpose of this study was to determine if noni juice reduces lipid hydroperoxide (LOOH) and malondialdehyde (MDA) derived-DNA adducts, markers of oxidative DNA damage, in peripheral blood lymphocytes of cigarette smokers.

Interventions

DIETARY_SUPPLEMENTNoni juice

Ingestion of noni juice, a source of iridoids, daily for 30 days.

DIETARY_SUPPLEMENTPlacebo

Sponsors

University of Illinois at Chicago
CollaboratorOTHER
Tahitian Noni International, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 to 65 years in age, smoker of more than 20 cigarettes per day, a smoking history exceeding one year, and willing to complete a one month trial.

Exclusion criteria

* concurrent use, or use in the previous three months, of prescription medication or antioxidant vitamins

Design outcomes

Primary

MeasureTime frameDescription
LOOH and MDA-DNA adducts1 monthLOOH and MDA-DNA adducts in lymphocytes immediately prior to intervention and at completion of intervention.

Secondary

MeasureTime frameDescription
adverse events1 monthAdverse health events

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026